Author Affiliations: Departments of Pharmacy (Drs Michel and Quelennec) and Internal Medicine, Diabetes, and Metabolic Disorders (Dr Andres), Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
We read with interest the excellent article by Mueller and colleagues1 about hospital-based medication reconciliation practices. We would like to offer some elements about our own experience. The evaluation of the potential clinical impact of the unintentional discrepancies identified and corrected during medication reconciliation process is particularly of high interest. Recently, we have set up conciliation at admission within our hospital and estimated in parallel the potential clinical significance of identified unintentional discrepancies by using a 3-category scale: level 1, “no potential harm”; level 2, “monitoring or intervention potentially required to preclude harm”; and level 3, “potential harm.”
Michel B, Quelennec B, Andres E. Medication Reconciliation Practices and Potential Clinical Impact of Unintentional Discrepancies. JAMA Intern Med. 2013;173(3):246–247. doi:10.1001/jamainternmed.2013.1235
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: